Although further studies are required to determine the effect of ACTN4 Nb on the progression of PCa in vivo, our results suggest that ACTN4 Nb can be a therapeutic molecule for the treatment of PCa. This evidence concerns the gene ACTN4 and posterior cortical atrophy.